Welcome to PsychU!

Early Episode Psychosis

Early-episode psychosis is a prime time for medical intervention, which may include multimodal therapies, case management, and a focus on self-determination. Treatment focuses on enabling individuals to move on from the acute impact of a psychotic episode and chart the course of their own recovery. In this Early Episode Psychosis Topic Library, find resources about treatment interventions and other information.

Featured Resources

Northwestern University Recovery From Early Episode Psychosis Program (REPP)

Northwestern University Recovery From Early Episode Psychosis Program (REPP)

Morris Goldman, MD, Stacy Prokopios, LCSW, and Lauren Walker, OTR/L, provide an overview of the Recovery from Early Episode Psychosis Program (REPP). First episode programs are recovery-oriented and enhance remission through multidisciplinary specialized services. ‘External’ barriers to recovery can often be mitigated by medication, education, reassurance, enhanced respect for boundaries,…
63% Of People With Schizophrenia Take Medications Raising Risk Of Cognitive Impairment

63% Of People With Schizophrenia Take Medications Raising Risk Of Cognitive Impairment

About 63% of people with schizophrenia take medications with anticholinergic properties associated with cognitive impairment. Anticholinergics are substances that block the action of the neurotransmitter called acetylcholine at synapses in the central and peripheral nervous system. This population’s anticholinergic cognitive burden (ACB) score averaged 3.0. At that score, their risk…

Upcoming Events

Ask A Question About Early Episode Psychosis

Enter your question in the box below and click “Ask My Question” to submit your inquiry.

You must be logged in to ask a question in this section.

Disclaimer: The information provided by PsychU is intended for your educational benefit only. It is not intended as, nor is it a substitute for medical care or advice or professional diagnosis. Treatment-related questions will not be addressed. Users seeking medical advice should consult with their physician or other healthcare professional.

Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) operates in a highly regulated and scrutinized industry. Therefore, we may not be able to address every questions or topic submitted. Topics which may not be addressed may include, but are not limited to questions related to: (1) specific medications, (2) branded items, (3) clinical or treatment advice relating to specific patient conditions. The lack of response to certain questions or comments should not be taken as an agreement with the view posed or an admission of any kind.


Request a free educational program for your organization or region today! These customizable PsychU presentations are available both online and in-person, and cover a range of topics including: schizophrenia, major depressive disorder, bipolar disorder, care coordination, quality standards, and more.

Top Requested Presentations

The Neuropsychiatric Inventory: Development & Applications

Diagnostic & Statistical Manual Of Mental Disorders–Fifth Edition (DSM-5): Key Updates VS DSM-IV-TR

Distinguishing Sedation From Efficacy In Antipsychotic Treatment

Learning Tracks